ClinicalTrials.gg
RecruitingNCT03236129DLI-BoostUpdated Dec 18, 2023

Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells

A Phase 3 interventional study of T-reg depleted DLI and Standard DLI in Hematological Malignancies, Regulatory T Cell Depletion and Relapse, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2023-12-18.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Feb 2018; still recruiting 8 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
52
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris — 6 open to participants now, 6 under way, 1 of them phase 3. Hematologic Neoplasms · Assistance Publique - Hôpitaux de Paris.

Started
2018
with 1 other
Phase 3
3 of 16
1 open now
Registered
8th of 16
by date

Among the 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris, this one is one of 2 that started in 2018, is one of 3 in phase 3, and was the 8th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

6 of the 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The investigators have previously shown the absence of toxicity of Treg-depleted-DLI and the possibility to triggering alloreactivity (GVHD/GVT) in relapsing patients dealing with hematological malignancies who had never shown any signs of GVHD after transplant or after one or more DLI.

The Investigators, we plan to demonstrate the benefit of Treg-depleted DLI as compared to the reference treatment of relapse in hematological malignancies after allogeneic HSCT which is currently based on standard DLI

Read the detailed description

This clinical trial is designed to demonstrate the benefit of Treg-depleted DLI as compared to the reference treatment of relapse in hematological malignancies after allogeneic HSCT which is currently based on standard DLI.

Patients who have never shown any signs of GVHD and for which one (or more) unmanipulated DLI have been ineffective. Those patients will receive a subsequent DLI, which will be either unmanipulated (control arm) or Treg depleted (experimental arm) after a randomization. In both cases, the second DLI will be immediately preceded by a lymphodepleting treatment based on cyclophosphamide and fludarabine association.

03

Conditions studied

  • Hematological Malignancies
  • Regulatory T Cell Depletion
  • Relapse

Keywords

  • DLI
  • Regulatory T cells depletion
  • Hematological malignancies
  • Relapse
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children and adults regardless of age or weight allograft for primary or secondary acute leukemia, MDS, lympho-proliferative syndrome (CLL, Myeloma, Lymphoma) or myelo-proliferative syndrome.
  • Prior HSCT (myeloablative or non-myeloablative conditioning) from a family donor geno-identical HLA or a volunteer donor HLA 10/10 or 9/10.
  • Molecular, cytogenetic, cytological relapse regardless of the date after the transplant.
  • Previous standard DLI should have brought a total dose of at least 5.10\^6 CD3 + / kg (donor HLA-geno idendique) or 2.10\^6 CD3 + / kg (voluntary donor) or 5.10\^5 CD3+/kg (donor haplo-idendique).
  • Patient corresponding to the failure criteria of a previous standard DLI, defined for each type of hematological in the test model "DLI-Treg-1" after a delay of at least 30 days in the case of a progressive disease after DLI and at least 60 days in the case of stable disease (due to possible delayed responses after DLI).
  • Patient consented to the study (the consent of both parents will be collected for minors)
  • Patients insured by a social security system.
  • Negative pregnancy test (β-HCG hormone) within the 7 days prior to enrollment

Exclusion criteria

Exclusion Criteria:

  • Presence of acute grade> II or extensive chronic GVHD since the first DLI
  • Patient receiving therapy for the treatment of GVHD or other reason
  • Impairment of liver function (transaminases> 5 N or > 50 µM except Gilbert's disease) or renal function ( \<30 ml / min)
  • OMS performance status > 2
  • Non controlled severe infection
  • Patient under tutorship, curatorship or legal protection

Donor Inclusion Criteria

  • Being the initial HSC donor (HLA geno-identical family or haplo-identique or non-family HLA 10/10 or 9/10)
  • Weight ≥20 kg authorizing the lymphapheresis
  • Having no for donating blood
  • Absence of severe heart failure, unstable heart disease, uncontrolled hypertension, type 1 diabetes
  • Negative serology for HIV1-2, , , HTLV 1 and VDRL/TPHA in the 30 days prior to apheresis. Negative viral genomics diagnosis is required for , HBV and HCV
  • Being informed of the study, and have given an oral non opposition
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Treg depleted DLI

    Patients will receive a lymphodepleting treatment combining cyclophosphamide and fludarabine followed by Treg depleted (Donor Lymphocytes Infusion (DLI)

    Procedure: T-reg depleted DLI

  • Active comparator
    Unmanipulated DLI

    Patients will receive a lymphodepleting treatment combining cyclophosphamide and fludarabine followed by a standard DLI (unmanipulated)

    Procedure: Standard DLI

Interventions

  • ProcedureT-reg depleted DLI

    The patients in the experimental arm benefit of a DLI depleted from regulatory T lymphocytes

  • ProcedureStandard DLI

    The patients in this arm benefit of a standard DLI.

06

What researchers measure

Primary outcomes

  1. Cumulative incidence of clinical manifestations of GVHD, in the form of acute GVHD with grade ≥ 2 and/or extensive chronic. This parameter will take into account the competitive risk of death unrelated to the GVHD

    Time frame: 3 month after injection

Secondary outcomes

  1. Cumulative incidence of relapse, taking into account the competitive risk of death unrelated to relapse

    Time frame: 1 year after injection

  2. Relapse-free survival

    Time frame: 1 year after injection

  3. Overall survival

    Time frame: 1 year after injection

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Maury S, Lemoine FM, Hicheri Y, Rosenzwajg M, Badoual C, Cherai M, Beaumont JL, Azar N, Dhedin N, Sirvent A, Buzyn A, Rubio MT, Vigouroux S, Montagne O, Bories D, Roudot-Thoraval F, Vernant JP, Cordonnier C, Klatzmann D, Cohen JL. CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation. Sci Transl Med. 2010 Jul 21;2(41):41ra52. doi: 10.1126/scitranslmed.3001302. PubMed 20650872 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2018 (actual). Primary completion is estimated for Feb 2025, 84 months after the start.

Of 41 phase 3 interventional studies under Hematologic Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 81. This study's planned 84 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2017
First posted
Aug 1, 2017
StartActual
Feb 22, 2018
Primary completionEst.
Feb 2025
CompletionEst.
Feb 2026
Last update
Dec 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03236129
Responsible party
Sponsor
First posted
Aug 1, 2017
Start date
Feb 22, 2018
Primary completion
Feb 2025 (estimated)
Completion
Feb 2026 (estimated)
Last update
Dec 18, 2023

Study contacts

Florence BECKERICH, MD
Contact
florence.beckerich@aphp.fr
(0)1 49 81 20 57 ext. +33
Sébastien MAURY, MD/ PhD
Contact
sebastien.maury@aphp.fr
(0)1 49 81 20 57 ext. +33
Florence BEKCERICH, MD
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion